Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.67 USD | -2.91% | +6.48% | -36.19% |
Jun. 04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.19% | 979M | |
+47.59% | 56.61B | |
-7.56% | 39.62B | |
+35.57% | 39.25B | |
-6.90% | 28.28B | |
+10.57% | 26.44B | |
-16.78% | 20.12B | |
+29.59% | 12.51B | |
+30.71% | 12.48B | |
-0.34% | 12.2B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Morgan Stanley Raises Price Target on Pharvaris to $35 From $32, Keeps Overweight Rating